Wpd Pharmaceuticals Inc · CSE:WBIO
Wpd Pharmaceuticals — Investor Presentation (September 2020)
38 slides from Wpd Pharmaceuticals's investor presentation, September 2020
Slide 1: WPD Pharmaceuticals Presentation for Investors
WPD Pharmaceuticals PRESENTATION FOR INVESTORS CSE:WBIO Investor Presentation | CSE:WBIO |
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believe",
Slide 3: Company Overview
Company WPD Pharmaceuticals is a diverse biotech company that has 8 novel drug candidates with 4 that are currently in clinical trials today with ongoing Overview collaborations at MD Anderson Cancer Center, Mayo Clinic, Emory University, Wake Forest University and leading hospitals and academic cen
Slide 4: Investment Highlights
Investment Highlights Experienced Management & Robust Drug Portfolio Strategic Partnerships Advisors 8 novel drug candidates across 4 Team of scientists with extensive indicators Wake Forest University Health pharmaceutical experience Sciences, Moleculin Biotech Inc. and CNS Pharmaceuticals, Inc. Ra
Slide 5: World-Class Pharmaceutical Team
Word-Class Pharmaceutical Team Investor Presentation | CSE:WBIO | 5
Slide 6: Mariusz Olejniczak and Beata Pająk
Mariusz Olejniczak Beata Pająk CHIEF EXECUTIVE OFFICER CHIEF SCIENTIFIC OFFICER Mariusz Olejniczak, CEO of WPD Pharmaceuticals is an experienced Biotechnologist with experience in the field of medical biology, professional in medicinal products, medical devices, supplements and including: oncology,
Slide 7: Walter Klemp and Peter Novak
Walter Klemp Peter Novak BOARD MEMBER BOARD MEMBER Mr. Klemp has 29 years of experience in start-up and high-growth Mr. Novak is a 30-year veteran of the insurance and financial services companies, the past nine of which have been spent developing FDA- industry, he is currently the General Agent of
Slide 8: Dr. Waldemar Priebe and Dr. Sigmund Hsu
Dr. Waldemar Priebe Dr. Sigmund Hsu FOUNDER, CHAIRMAN OF SCIENTIFIC SCIENTIFIC ADVISORY BOARD ADVISORY BOARD Dr. Waldemar Priebe, Ph.D., is a world renowned medicinal chemist and Dr. Sigmund Hsu has extensive experience in the evaluation and entrepreneur. Dr. Priebe is a Professor of Medicinal Chemi
Slide 9: Tomasz Rejman and Dr. Tomasz Skorski
Tomasz Rejman Dr. Tomasz Sikorski STRATEGIC ADVISORY BOARD SCIENTIFIC ADVISORY BOARD Mr. Rejman has held senior management positions at McKinsey, Allianz Dr. Tomasz Skorski is currently a Professor at The School of Medicine at and Cersanit / Rovese managing over 6,000 employees and in charge of Temp
Slide 10: Dr. Sandra Silberman and Dr. Donald Picker
Dr. Sandra L. Silberman Dr. Donald Picker SCIENTIFIC ADVISORY BOARD SCIENTIFIC ADVISORY BOARD Dr. Sandra L. Silberman, M.D., Ph.D. is a Hematologist/Oncologist who Donald Picker, PhD, joined the Moleculin team in 2009 with over 35 earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University ye
Slide 11: 8 Drugs, 5 Indications
8 Drugs 5 Indications Investor Presentation | CSE:WBIO | 11
Slide 12: Drug Pipeline
Discovery Pre-Clinical Regulatory Clinical I / II Brain Cancers WPD101 Berubicin WP1066 Pancreatic Cancers WP1066 WP1732 Other Cancers WPD103 Annamycin WPD1220 Melanoma WPD102 Investor Presentation | CSE:WBIO | 12
Slide 13: WPD101
01 WPD101 Indications to Treat Brain Cancers including Glioblastoma Investor Presentation | CSE:WBIO | 13
Slide 14: WPD101 Overview
WPD101 OVERVIEW INITIAL INDICATION Cancer cells, including glioblastoma (GBM) tumor cells that are highly resistant to all known therapies, Primary focus on GBM and express tumor specific receptors, IL-13RA2 and EphA2 (these receptors are not present in normal cells). subsequently on other cancers w
Slide 15: WPD101 Grants, Regulatory, Market Opportunity
WPD101 GRANTS / FUNDING MARKET OPPORTUNITY • In February 2018, WPD was awarded an $6 million-dollar grant from the National Centre for With no other curative options Research and Development in Poland for the development of WPD101 that would include Phase available, we believe WPD101 may I clinical
Slide 16: WPD102
02 WPD102 Indications to Treat Uval Melanoma Investor Presentation | CSE:WBIO | 16
Slide 17: WPD102 Overview
WPD102 OVERVIEW INITIAL INDICATION Uveal melanoma (UV), a rare but deadly cancer of the eye that often rapidly progresses to the liver is Primary focus on primary UV and characterized by the expression of the tumor specific receptors IL-13RA2, which are not detected in subsequently on liver UV lesio
Slide 18: WPD102 Grants, Regulatory, Market Opportunity
WPD102 GRANTS / FUNDING MARKET OPPORTUNITY • In February 2019, WPD started developing an updated scientific program and grant proposal for With no other curative options submission in 2019/2020 available, we believe WPD102 may have the potential for accelerated approval as a safe and effective REGUL
Slide 19: Berubicin
03 Berubicin Indications to Treat Glioblastoma Investor Presentation | CSE:WBIO | 19
Slide 20: Berubicin Overview
Berubicin OVERVIEW INITIAL INDICATION Berubicin is an exciting new drug that is one of the first anthracyclines proven to cross the blood brain GBM barrier (BBB) and able to reach brain tumors. This discovery can potentially extend the clinical use of anthracyclines to brain tumors, specifically GBM
Slide 21: Berubicin Grants, Regulatory, Market Opportunity
Berubicin GRANTS / FUNDING MARKET OPPORTUNITY • In February 2019, WPD was awarded a $6 million-dollar grant from the National Centre for With no other curative options Research and Development in Poland for the continued development of Berubicin in adult available, we believe Berubicin and in pediat
Slide 22: WP1066
04 WP1066 Indications to Treat CNS tumors, Pancreatic cancer, Ocular tumors Investor Presentation | CSE:WBIO | 22
Slide 23: WP1066 Overview
WP1066 OVERVIEW INITIAL INDICATION WP1066 represents a new class of drugs, which WPD calls “Immune/Transcription Modulators.” WP1066 Glioblastoma(GBM) and melanoma and related analogs have not only demonstrated the ability to directly induce apoptosis (tumor cell brain metastases. Due to the death)
Slide 24: WP1066 Grants, Regulatory, Market Opportunity
WP1066 GRANTS / FUNDING MARKET OPPORTUNITY • WP1066 development has received over $8 million and grants and has had $15 million invested in The expected market size is furthering the technology and is expected to receive an additional $3 million in the next 24 multiple billions. months for Phase I a
Slide 25: WP1732
05 WP1732 Indications to Treat Pancreatic Cancer Investor Presentation | CSE:WBIO | 25
Slide 26: WP1732 Overview
WP1732 OVERVIEW INITIAL INDICATION Based on preclinical testing, WP1732 is a potential breakthrough discovery, a new fully water-soluble p- Pancreatic Cancer STAT3 inhibitor technology complementary to orally bioavailable non-water-soluble WP1066. STAT3 inhibitors are an essential part of our effort
Slide 27: WP1732 Grants, Regulatory, Market Opportunity
WP1732 GRANTS / FUNDING MARKET OPPORTUNITY • WP1732 has benefitted from over $1 million in grants and subsequently sponsored research at MD The expected market size is in Anderson Cancer Center and is expected to receive over $3 million in the next 24 months for Phase excess of $1 billion. I and II
Slide 28: WP1220
06 WP1220 Indications for cutaneous T-cell lymphoma. Investor Presentation | CSE:WBIO | 28
Slide 29: WP1220 Overview
WP1220 OVERVIEW INITIAL INDICATION Cutaneous T-cell lymphoma (CTCL) is rare and difficult to recognize malignant tumor of the lymphatic Cutaneous T-cell lymphoma system. The disease is caused by an uncontrolled increase in T lymphocytes located in the lymphatic system of the skin and often mistaken
Slide 30: WP1220 Partners and Market Opportunity
WP1220 PARTNERS, AFFILIATIONS & LICENSE MARKET OPPORTUNITY • MD Anderson, leading cancer research center in the world The expected market size is in • Moleculin Biotech, Inc. – co-development partner excess of $1 billion. Investor Presentation | CSE:WBIO | 30
Slide 31: WPD103
07 WPD103 Indications to Treat GBM, Melanoma, & Other Cancers Investor Presentation | CSE:WBIO | 31
Slide 32: WPD103 Overview
WPD103 OVERVIEW INITIAL INDICATION WPD103 is a radiopharmaceutical based on the expression of tumor specific receptors, such as IL-13RA2 Primary focus on cancers with high and EphA2, which are not detected in normal cells, which express mainly IL-13RA1 and Eph-RA1 proteins. overexpression of IL-13RA
Slide 33: WPD103 Grants, Regulatory, Market Opportunity
WPD103 GRANTS / FUNDING MARKET OPPORTUNITY • In July 2018, WPD started developing a scientific program and grant proposal for submission in With no other curative options 2019/2020 available, we believe WPD103 may have the potential for an early REGULATORY approval and to become a highly effective a
Slide 34: Annamycin
08 Annamycin Indications to treat AML, metastasis to lungs Investor Presentation | CSE:WBIO | 34
Slide 35: Annamycin Overview
Annamycin OVERVIEW INITIAL INDICATION Annamycin belongs to the group of anthracyclines, considered one of the most effective groups of …. oncological drugs. Unlike clinically used anthracyclines, Annamycin, thanks to modifications in the drug structure, effectively penetrates cancer cells, regardles
Slide 36: Annamycin Grants, Regulatory, Market Opportunity
Annamycin GRANTS / FUNDING MARKET OPPORTUNITY • TBD With no other curative options available, we believe WPD102 may REGULATORY have the potential for accelerated approval as a safe and effective • Liposomal Annamycin is now in the clinical development for the treatment of AML in Europe and US. thera
Slide 37: Corporate Overview: Capital Structure
Corporate Overview WPD Pharmaceuticals Inc. Capital Structure Issued and Outstanding 111,520,388 CSE: WBIO Warrants Fully Diluted 3,949,997 115,470,385 Management and Insider holdings 36% Investor Presentation | CSE:WBIO | 37
Slide 38: Contact
Contact Vancouver Office Warsaw Office Suite 1080 Żwirki i Wigury 101 789 West Pender St 02-089 Warszawa Vancouver, BC V6C 1H2 Poland investors@wpdpharmaceuticals.com wpdpharmaceuticals.com CSE:WBIO Investor Presentation | CSE:WBIO |
WPD Pharmaceuticals — Investor Presentation (September 2020) on 6ix